PTC Therapeutics, Inc. (PTCT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $69.21, PTC Therapeutics, Inc. (PTCT) is priced for today's economics sustained for ~6.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-08-08.

Generated: 2026-08-08 · Source: https://boothcheck.com/report/PTCT

Headline

FieldValue
TickerPTCT
CompanyPTC Therapeutics, Inc.
Sector / IndustryHealthcare
Current price$69.21/sh

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)5.0%
Operating margin today12.5%
Margin compression (value-band)-7.5pp
Must persist for6.3y
Multiple paid34x operating income

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.9% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
sustained it ~6.3 years at this level33%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings—0—
Relative1.82x2expensive
Growth—0—

Families that call it expensive: Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.7%); the inversion above states its own rate.

Per-Model Detail (n=2)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$48.351.43xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset——no—
Two-Stage Excess ReturnAsset——no—
Discounted Future Market CapGrowth$30.002.31xnoRev $1.0B, growth 2% (input: historical growth; tapered), Terminal P/S: 4.8x / 5.7x / 6.6x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$31.342.21xyesEBITDA $0.14B × sector EV/EBITDA 16.0x
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$48.351.43xnoRevenue $1.01B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$1.6b
Net debt / NOPAT (after-tax)-15.15x (net cash)
Net debt / operating income (pre-tax)-12.97x (net cash)
Share count CAGR (dilution)6.6%
Burning cashyes

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

The market is paying roughly 34 times company-wide operating income for PTC Therapeutics, which reads as a demanding number until you look at what produced the denominator. Trailing operating income of about 126 million dollars is the residue of a portfolio in the middle of a handover: one product in its first full year of launch, two older ones in decline, and a royalty stream that is large but partly promised elsewhere. The June quarter is the cleaner picture. Total revenue reached 361 million dollars, product revenue 238.8 million, and net income came in at 83.5 million against a loss of 64.8 million in the same quarter a year earlier. That is a company crossing over, and a trailing multiple built across the crossing describes neither side of it well.

Sephience is the reason. Approved for phenylketonuria, it produced 151.3 million dollars in the June quarter, up 21% on the March quarter, with 1,647 patients on commercial therapy worldwide. The 10-Q is direct about the source of the lift: net product revenue was $225.6 million for the three months ended March 31, 2026, an increase of $72.1 million, or 47%, from $153.4 million for the three months ended March 31, 2025. The increase in net product revenue was primarily due to an increase in net product sales of Sephience, which is in the first year of its launch. Rare-disease launches are slow to start and then behave unlike ordinary drug launches, because the patients are identifiable, the prescribers are few, and once a patient starts they generally stay. Management raised full-year product revenue guidance to a range of 850 to 950 million dollars and total revenue guidance to 1.18 to 1.28 billion.

Behind the products sits an unusual second income line. PTC discovered risdiplam, which Roche sells as Evrysdi for spinal muscular atrophy, and it collects a royalty on those sales. The 10-K states the arrangement plainly: In accordance with the SMA License Agreement, we record royalty revenues based on worldwide annual net sales of Evrysdi. Roche reported year-to-date Evrysdi sales of roughly 968 million Swiss francs, which produced 71.1 million dollars of royalty revenue to PTC in the June quarter against 57.6 million a year before. A royalty on someone else's commercial machine carries no sales force, no manufacturing and no launch risk. It is the highest-quality revenue a company of this size can own, with the important qualification, addressed below, that PTC has already sold a large part of it.

The pipeline is funded by other people to an unusual degree. Novartis is running and paying for INVEST-HD, the Phase 3 trial of votoplam in Huntington's disease, targeting roughly 770 patients with early symptomatic disease; dosing the first patient triggered a 50 million dollar milestone to PTC in the June quarter. The supporting data are real rather than hopeful: 24-month results from the PIVOT-HD extension showed dose-dependent slowing on a composite Huntington's rating scale, reaching 52% at the 10 mg dose in stage 2 participants. Behind that sit a restart study in Friedreich's ataxia, a first-in-human trial of an oral NLRP3 inhibitor, and a next-generation DHODH program. A company that runs a Phase 3 in Huntington's disease without paying for it is running a pipeline its own income statement could not otherwise carry.

Bear Case

Look at the liabilities side before the assets, because that is where this company differs from its own headline. PTC sold the future Evrysdi royalty to Royalty Pharma rather than keeping it. The 10-K sets out the second tranche: we sold to Royalty Pharma our retained right to receive sales-based royalty payments, or the Royalty, on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement under the SMA Program in exchange for $240.0 million in upfront cash consideration. Accounting treats that as borrowing against a stream rather than as a sale, so a liability for the sale of future royalties sits on the balance sheet and unwinds through non-cash interest. In 2025 that liability began the year above 2.0 billion, absorbed 228.6 million of royalty revenue payable onward to Royalty Pharma, and accrued 215.2 million of non-cash interest, ending higher than it started. The royalty line in the income statement is therefore doing two jobs at once, and only part of it ends up as money the company keeps.

That reframes the balance sheet. Holdings of equivalents and marketable securities were 2.23 billion dollars at the end of June, against 600 million of funded borrowings, and stated that way the position looks unassailable. It is genuinely strong. But the obligation attached to the sold royalty is roughly the same order of magnitude as the securities, and it is settled out of a revenue line the company still reports as its own. A reader who nets only the borrowings against the securities is reading half the capital structure.

The second pressure is that two of the four products are shrinking, visibly and for structural reasons. Translarna produced 42.2 million dollars in the June quarter against 59.5 million a year earlier. Emflaza produced 24.6 million against 36.4 million, with generic erosion named as the cause. Neither decline is a surprise and neither is likely to stop. The whole growth case therefore rests on one product in its first year, and the guidance range for full-year product revenue, 850 to 950 million dollars, is wide precisely because a first-year launch curve is hard to call. If Sephience lands at the bottom of that range while the older products keep decaying at the observed pace, the operating base the price is capitalised on does not grow into the multiple. It waits.

Which brings the question back to what the price requires. Today's price capitalises about 34 times company-wide operating income, and the arithmetic that gets there needs operating growth pinned at the fastest pace the business could fund out of its own cash flow, held for about six years. Of companies that have grown that fast, only about a third sustained it that long. Read the confidence honestly: that comparison is thin, resting on the peer multiple range with no usable read on the company's own history, and a thin read is a weaker claim rather than a gentler one. Six years is also longer than the useful life of a first-year launch curve. Somewhere inside that window, Sephience has to stop being the growth story and something in the pipeline has to take over.

Valuation

What is today's price actually asking of this business? Roughly 34 times company-wide operating income, and the way that number is reached is by assuming operating growth runs at the fastest rate the company could fund from its own cash flow and stays there for about six years. State it that way and the bet becomes checkable. It is not a bet on any single trial. It is a bet on duration.

History gives a partial answer. Among comparable fast-growing companies, only about a third held that pace for that long. Two of the four available comparisons produced usable evidence, which leaves the reading directional rather than settled, and that thinness lowers confidence in the label rather than softening it. On the evidence that does exist, the requirement sits inside the plausible range rather than outside it. That is a meaningfully different situation from a company whose price needs something no comparable business has managed.

The methods disagree with the price, and they disagree in one direction only. The peer-multiple family is the only one that resolves at all here, and it lands well under the price, at a little over half of it. The earnings-power and asset lenses produce nothing usable, for the ordinary reason that trailing GAAP earnings are negative and the balance sheet of a drug company carries almost no tangible value that matters. Look at how the peer-multiple readings are constructed and you see why they land low: one applies a sector price-to-sales ratio of 4.0 times to about 1.01 billion dollars of revenue, and the other applies a sector enterprise-to-EBITDA of 16.0 times to roughly 0.14 billion of EBITDA. Both are category averages pressed onto a company with a royalty stream, a first-year launch and two declining products. They are a floor built from an average, not a valuation of this particular mix.

The margin picture explains the rest of the distance. The business earns about 12.5% at the operating line today. The price only needs it to hold about 5% while the top line compounds, which is a low bar on margin and a high one on persistence. In other words the market is not paying for PTC to become more profitable per dollar of revenue. It is paying for a lot more dollars of revenue for a long time.

The balance sheet decides how long the company can be wrong about the timing. Equivalents and marketable securities stood at 2.23 billion dollars at the end of June, and funded borrowings at 600 million, of which the newest piece is 550 million of convertible notes issued in June 2026 at a zero coupon and due 2031. Zero coupon means no interest to service, and 2031 means nothing to refinance before then. Trailing operating income is positive and the June quarter produced net income, so this is not a company living off its balance sheet. Set against that is the liability for the sale of future royalties described above, which is settled out of revenue the company still books. Share count has grown at about 6.6% a year over the four years to June, a pace closer to option and equity compensation than to repeated rescue financing. The company has time. What it does not yet have is proof that the next product can do what Sephience is doing now.

Catalysts

The nearest item on the calendar is a conversation rather than a readout. PTC plans to engage the FDA in the second half of 2026 on the 24-month PIVOT-HD results for votoplam in Huntington's disease, which showed dose-dependent slowing on a composite rating scale reaching 52% at the 10 mg dose in stage 2 participants. What comes out of that meeting sets whether the Huntington's program has a route to market shorter than the full Phase 3, which Novartis is running and funding with roughly 770 patients targeted. The distinction matters commercially. One path is years away and paid for by a partner; the other is nearer and would change the shape of the company.

Two studies start in the current quarter. The PROVE-FA trial in Friedreich's ataxia is expected to begin in the third quarter of 2026, enrolling about 120 patients aged 7 to 21 with an open-label treatment arm against a matched natural history control, and it exists to support a resubmission of the vatiquinone application after the first one did not clear. A Phase 2a study of PTC844, a next-generation DHODH inhibitor, is also expected to start in the third quarter. Earlier in the year the company began a first-in-human study of PTC612, an oral NLRP3 inhibitor, and named PTC303 as the development candidate from its MSH3 splicing program, aimed at Huntington's disease and myotonic dystrophy, with clinical entry planned for 2027.

The recurring commercial event is the quarterly Sephience number. Guidance for full-year product revenue was raised to a range of 850 to 950 million dollars and total revenue to 1.18 to 1.28 billion, and both rest on a launch curve in its first year. The check to run each quarter is the patient count against the revenue: 1,647 patients were on commercial therapy worldwide at the end of June, so revenue per patient and the rate of new starts, rather than the headline alone, are what show whether the launch is broadening or simply reaching the same prescribers more often.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q2 2026 results release, July 30, 2026 · FY2025 annual report, royalty note

View the full interactive PTCT report on boothcheck